Evidence that cyclosporin A prevents clinical cardiac allograft rejection by blocking both direct and indirect antigen presentation pathways
Monitoring for the responses to alloantigens presented either by the direct or the indirect presentation pathway have been reported to be of clinical value after kidney transplantation. Amongst others, the level of these responses may be dependent on the immunosuppressive treatment. We studied both presentation routes in peripheral blood mononuclear cells (PBMC) of cardiac transplant patients, who experienced episodes of rejection, and related them to the in vivo cyclosporin A (CsA) levels in plasma. PBMC of the recipients were stimulated with irradiated donor cells to determine the direct presentation pathway. As a method for the activation of the immune response via the indirect pathway, PBMC were stimulated with tetanus toxoid. Both immune responses increased when CsA levels inadvertently decreased to inadequate concentrations and histological rejection was diagnosed. After clinical heart transplantation, CsA may prevent rejection by blocking both the direct and the indirect antigen presentation pathway.
Key wordsClinical transplantation Presentation pathways Cyclosporin A Rejection
Unable to display preview. Download preview PDF.
- 1.Besouw NM van, Vaessen LMB, Daane CR, Jutte NHPM, Balk AHMM, Claas FHJ, Weimar W (1996) Peripheral monitoring of direct and indirect presentation pathways in clinical heart transplant recipients. Transplantation (in press)Google Scholar
- 2.Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A (1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Lung Transplant 9: 587–593Google Scholar
- 4.Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB (1995) The indirect pathway of allorecognition. The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. Transplantation 59: 612–616PubMedGoogle Scholar